Home > Healthcare > Pharmaceuticals > Finished Drug Form > Acromegaly Treatment Market

Acromegaly Treatment Market Share

Report ID: GMI9820
Published Date: Jun 2024
Report Format: PDF

Download Free Sample

Acromegaly Treatment Market Share

The acromegaly treatment industry is characterized by several pharmaceutical companies vying for market share. Key players are dominating the market with their extensive portfolios of somatostatin analogs, growth hormone receptor antagonists, and other therapeutic options. The companies invest significantly in R&D to innovate new treatments and improve existing ones to sustain their position in the market. Additionally, strategic collaborations, mergers, and acquisitions are common tactics employed to strengthen the market presence and expand product offerings.

Acromegaly Treatment Market Companies

Few of the prominent players operating in the acromegaly treatment industry include:

ADVANZ PHARMA
Amryt Pharma Plc
Chiasma, Inc
Cipla
Crinetics Pharmaceuticals Inc
Dauntless Pharmaceuticals
Eli Lilly and Company
Ipsen SA
Novartis AG
Pfizer Inc.
Sun Pharmaceutical Industries Ltd.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Acromegaly treatment industry size was worth USD 2.2 billion in 2023 and is projected to expand at 5.4% CAGR from 2024 to 2032, owing to the rising prevalence and incidence of acromegaly and pituitary tumors.

The pseudo acromegaly type segment in the acromegaly treatment industry is projected to record USD 1.3 billion in 2023 and is estimated to depict 5.3% CAGR between 2024 and 2032, due to its increasing diagnosis and recognition.

The medical therapy treatment segment in the acromegaly treatment industry recorded 45.7% share in 2023 due to its effectiveness and convenience of pharmacological interventions compared to surgical options.

U.S. acromegaly treatment market industry size was USD 876.4 million in 2023 and is estimated to grow at substantial CAGR between 2024 and 2032, due to its large population and high healthcare spending.